FRCA Notes


Traumatic Brain Injury

The curriculum calls for understanding of the 'anaesthesia for emergency surgery for traumatic brain injury' and 'the neurocritical care management of traumatic brain injury'.

The February 2024 CRQ on this topic was 'reassuringly well answered', although the examiners expected more knowledge on indications for CT heads and causes of raised JVO2.

A repeat of the CRQ in 2025 was 'well answered and had a high pass rate'.

Resources


  • TBI is the leading cause of disability and death in young adults in the developed world
  • An increasing proportion of cases now occur in older, frailer patients with comorbidities

  • Classified according to GCS after resuscitation
    • Mild: GCS 13 - 15
    • Moderate: GCS 9 - 12
    • Severe: GCS ≤8

  • GCS-based classification is pragmatic but does not capture the underlying pathology; patients with similar GCS can have very different injuries and prognoses
  • The newer clinical-biomarker-imaging-modifier (CBI-M) framework is a more multidimensional approach, but is currently mostly a research tool

  • Up to 80% occur in male patients
  • Incidence 1.4million/year
  • Mortality 6 - 10/100,000/yr

  • Minor head injuries (89%):
    • Falls (22 - 43%)
    • Assault (30 - 50%)
    • RTCs (25%)

  • Moderate-severe head injuries (11%) are mostly from RTCs

Primary injury

  • Primary injury occurs as a direct consequence of the physical insult
  • Prevention of primary injury is largely a public health challenge

  • Direct impact, acceleration-deceleration and rotational shearing forces cause:
    • Bony fractures
    • Brain parenchyma contusion, haemorrhage, oedema
    • Diffuse axonal injury

  • Microscopically there is:
    • Neuronal cell wall disruption and BBB disruption
    • Increasing membrane permeability and disrupted ionic homeostasis

Secondary injury

  • Neurological injury progresses over the ensuing hours to days
  • Secondary injury is potentially modifiable and is therefore the principal target of ICU care

  • Inflammatory and neurotoxic processes cause cytotoxic and vasogenic oedema, leading to:
    • Cerebral oedema & hyperaemia → raised ICP and reduced intracranial compliance
    • Disruption of the BBB
    • Hypoperfusion & impaired cerebral autoregulation
    • Cerebral ischaemia (focal & general)
    • Release of excitatory neurotransmitters e.g. glutamate, aspartate
    • Mitochondrial dysfunction and calcium influx → cellular energy failure
    • Release of high levels of oxygen free radicals
    • Cell death and apoptosis

  • Secondary injury is exacerbated by other physiological insults e.g. hypoxia, hypo/hypercapnia, hypotension, hyperthermia and hypo/hyperglycaemia

Pre-hospital care

    • Standard trauma care
    • Aim to treat:
      • Hypoxia; correlates with worse outcome
      • Hypotension; single episodes are associated with increased morbidity and mortality, while the frequency and duration of hypotension correlates with mortality

Initial management


System Targets
Airway I&V (see below)
Respiratory Saturations >97%
PaO2 >10-13kPa
Normocapnia: PaCO2 4.7 - 5.3kPa
Cardiovascular MAP >90mmHg
Manage haemorrhage (commonest cause of hypotension)
Reverse anticoagulants
Avoid albumin (SAFE trial: ↑ mortality)
Neurological Maintain CPP 60 - 70mmHg
Treat ICP >22mmHg
Treat seizures
Sedation and analgesia
Metabolic Na+ 145 - 155mmol/L
Glucose 6 - 10mmol/L
Normothermia 36 - 37°C; avoid hyperthermia

Imaging


NICE criteria for CT scanning in head injury
GCS <13 on initial assessment
GCS <15 at two hours post-injury on assessment
Suspected open or depressed skull fracture
Any sign of basal skull fracture (haemotympanum, CSF otorrhoea/rhinorrhoea, Battle's sign, panda eyes)
Post-traumatic seizure
Focal neurological deficit
>1 episode of vomiting since head injury
LOC or amnesia + >65yrs, dangerous mechanism, >30mins retrograde amnesia or clotting/bleeding disorder

  • Trauma CT including brain and C-spine
  • MRI is logistically complex, takes longer and is rarely used in the acutely unwell
  • Skull X-rays are only used as part of a skeletal survey in a child with NAI

Transfer

  • Initial resuscitation and stabilisation should be completed before transfer
  • Time-critical transfer to neurosurgical centre

  • I&V is the gold standard for airway management
  • Patients are at higher risk from:
    • Existing hypoxia
    • Intra-cranial hypertension
    • Full stomach
    • Coalescing injuries:
      • C-spine instability
      • Maxillofacial trauma

  • Indications for invasive ventilation:

  • System Indication
    Airway Loss of airway protective reflexes
    Facial trauma inc. bilateral mandible fracture, skull base fracture
    Respiratory Respiratory failure: hypoxaemia or hypercarbia
    Spontaneous hyperventilation causing PCO2 <4kPa
    Neurological Low GCS: ≤8
    Deteriorating GCS: motor score decrease >2 points
    Seizures

Process

  • Full AAGBI monitoring
  • Use of emergency intubation checklist
  • Modified RSI
  • Maintain C-spine control with MILS
  • Opioids to obtund hypertensive response to laryngoscopy
  • Propofol (or ketamine) + rocuronium

Ventilation

  • Lung-protective ventilation with attention to intracranial dynamics
  • PEEP should be individualised:
    • Moderate PEEP may improve oxygenation
    • Excessive PEEP ↑ intrathoracic pressure, impairs cerebral venous return and can worsen intracranial hypertension

  • ICU management aims to limit secondary brain injury by optimising cerebral perfusion, oxygenation and metabolic demand
  • Fixed ICP and CPP thresholds are pragmatic, population-derived targets but individual physiology varies between patients and over time

ICP monitoring

  • ICP monitoring is recommended in severe TBI (GCS ≤8) with an abnormal CT, or in selected high-risk patients with a normal CT
  • Intervene when ICP >22mmHg
  • Outcome relates to the overall burden of intracranial hypertension (magnitude and duration), not just whether a threshold is crossed

  • CPP = MAP - ICP
    • Both MAP and ICP should be referenced at the level of the external auditory meatus
    • Target CPP 60 - 70mmHg as this balances hypoperfusion at lower CPP against ↑ cerebral blood volume and oedema at higher CPP

  • Non-invasive techniques (transcranial Doppler, optic nerve sheath diameter, automated pupillometry) may identify those at risk but do not replace invasive monitoring
  • Invasive monitoring options include:

    • Intraparenchymal probes:

Advantages Disadvantages
Relatively easy to insert
Lower infection risk
Cannot be recalibrated once inserted
No CSF drainage

    • External ventricular drain (EVD):

Advantages Disadvantages
Accurate pressure measurement
Allows therapeutic CSF drainage
Higher infection risk (ventriculitis)
Technically more complex
Haemorrhage, overdrainage

  • The ongoing ICU management one can instigate for raised ICP in TBI can be stratified into three tiers, escalating from low-risk to high-risk measures

Tier 1: routine low-risk measures

  • Head up 15 - 30°, neutral head and neck position, avoid jugular venous obstruction

  • Sedation and analgesia to ↓ cerebral metabolic demand and prevent agitation:
    • Propofol is usually first-line; limited by hypotension and risk of propofol infusion syndrome
    • Midazolam if haemodynamically unstable; accumulates and delays neurological assessment
    • Ketamine is an adjunct rather than standard care; does not consistently ↑ ICP and may suppress spreading cortical depolarisations

  • Normothermia 36 - 37°C and treat fever promptly
  • Prophylactic or therapeutic hypothermia is not recommended due to lack of benefit (POLAR) or poorer functional outcome (Eurotherm3235)

  • Normocapnia: PaCO2 4.7 - 5.3kPa
  • Intermittent CSF drainage if EVD in situ
  • Maintain CPP 60 - 70mmHg

  • Acute rises in ICP should prompt re-examination and consideration of a repeat CT for a surgically amenable lesion

Tier 2: targeted medical management

  • Bolus osmotherapy:
    • Creates an osmotic gradient across the BBB, drawing water into the intravascular space
    • No clear evidence favouring mannitol or hypertonic saline
    • Intermittent boluses preferred for acute rises in ICP

Agent Typical dose Notes
Mannitol 0.25 - 1g/kg Hypovolaemia, hypotension, renal dysfunction
Caution if osmolar gap >20mOsm/kg
Hypertonic saline 3%: 1 - 2ml/kg
23.4%: 0.25 - 0.5ml/kg
Expands intravascular volume; useful if haemodynamically unstable
Titrate to serum Na+

    • Monitor sodium and osmolality; pragmatic upper limits of Na+ 155 - 160mmol/L and 320mOsm/kg

  • Neuromuscular blockade:
    • Prevents coughing, straining, shivering and ventilator dyssynchrony
    • Use selectively (e.g. refractory ICP, severe dyssynchrony) and for the shortest duration
    • Masks seizures and neurological deterioration; critical illness weakness

  • Short-term hyperventilation to PaCO2 4.0 - 4.7kPa:
    • Reserved for acute deterioration or impending herniation while definitive therapy is instituted
    • Avoid prophylactic or sustained hyperventilation, particularly in the first 24hrs when CBF is often critically low; risks cerebral ischaemia

Tier 3: rescue high-risk measures

  • Barbiturate coma:
    • ↓ cerebral metabolic demand with coupled ↓ CBF and ICP
    • Titrated to burst suppression on continuous EEG; many centres target 50 - 80% suppression
    • No clear improvement in functional outcome
    • Hypotension (may offset any CPP benefit), myocardial depression, immunosuppression, ileus, delayed awakening

  • Decompressive craniectomy:
    • Increases intracranial volume and compliance; effective at lowering ICP
    • DECRA: early bifrontal craniectomy for diffuse TBI with moderate ICP elevation worsened functional outcome
    • RESCUEicp: late rescue craniectomy for refractory ICP reduced mortality, but with more survivors in a vegetative state or with severe disability
    • Reserve for carefully selected patients after medical optimisation, with patient-centred discussion of likely outcomes

Advanced neuromonitoring

  • Aims to individualise physiological targets although has not yet been shown to improve patient-centred outcomes

  • Autoregulation-guided CPP (CPPopt):
    • Pressure reactivity index (PRx) is a continuous correlation between slow changes in arterial pressure and ICP
    • Negative or near-zero PRx implies intact autoregulation (↑ MAP causes vasoconstriction and ↓ ICP)
    • Positive PRx implies impaired autoregulation (ICP passively follows MAP)
    • CPPopt is the CPP at which PRx is lowest

  • MAP challenge: ↑ MAP by ~10mmHg for up to 20mins and observe ICP
    • If ICP falls then autoregulation is intact and may benefit from a higher CPP target
    • If ICP rises then autoregulation is impaired and avoid further vasopressor augmentation

  • Brain tissue oxygen tension (PbtO2):
    • Low PbtO2 is independently associated with worse outcome, even with apparently adequate ICP and CPP
    • Responds to FiO2, Hb and cerebral perfusion
    • Reduces cerebral hypoxia, but functional benefit unproven and carries risks of probe insertion (haemorrhage, focal injury)

Other management

  • Transfusion:
    • Hb 70g/L is reasonable in stable patients without evidence of cerebral hypoxia
    • Consider a higher target (80 - 100g/L) with intracranial hypertension, low PbtO2 or impaired autoregulation (HEMOTION, TRAIN)

  • Glycaemic control: target 6 - 10mmol/L
    • Hyperglycaemia is associated with worse outcome
    • Tight control risks hypoglycaemia and ↓ cerebral glucose availability despite acceptable systemic values

  • Seizure prophylaxis:
    • Early (<7 days) vs late (>7 days) post-traumatic seizures can occur
    • Prophylaxis reduces early seizures only but does not prevent late seizures or post-traumatic epilepsy, nor improve functional outcome
    • Options include:
      • Phenytoin (BTF recommended): 20mg/kg load then 4 - 6mg/kg/day
      • Levetiracetam widely used (1 - 2g load then 500 - 1,500mg BD) due to ease of use and fewer interactions, although not proven superior
    • Limit to 7 days unless clinical or electrographic seizures - consider continuous EEG if non-convulsive seizures suspected

  • VAP occurs in ~20% and is associated with worse outcome; early ceftriaxone reduces early VAP but is not routinely recommended
  • VTE prophylaxis
  • Adequate nutrition

Prognostication

  • Uncertain and dynamic
  • Should not rely on single variables e.g. GCS, pupillary reactivity, age
  • Prognostic models (IMPACT, CRASH) perform reasonably at a population level but are imperfect for individuals

  • Multimodal approach:
    • Serial neurological examination as sedation is weaned and confounders corrected
    • CT and MRI (particularly if diffuse axonal injury suspected)
    • EEG

  • Avoid early pessimistic predictions and delay definitive conclusions until confounders resolve and the recovery trajectory is clearer
  • Outcome lies on a spectrum (e.g. GOSE) so shared decision-making should incorporate patient values